Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: CircPTPN22 modulates T-cell activation by sponging miR-4689 to regulate S1PR1 expression in patients with systemic lupus erythematosus

Fig. 1

Expression of circPTPN22 in patients with SLE and its clinical relevance. A Relative expression of circPTPN22 in 44 HCs and 45 patients with SLE. B CircPTPN22 expression was lower in patients with SLE and higher SLEDAI scores. C Correlation analysis of circPTPN22 expression and SLEDAI. The expression of circPTPN22 in patients with SLE, with or without skin involvement (D), alopecia (E), arthritis (F), lupus nephritis (G), leukopenia (H), anti-dsDNA ( +) (I), anti-Sm ( +) (J), and C3 or C4 deficiency (K), was compared. L. Expression of circPTPN22 among SLE patients receiving prednisone ≤ 30 mg/day and > 30 mg/day was compared. HCs healthy controls, SLE systemic lupus erythematosus, SLEDAI Systemic Lupus Erythematosus Disease Activity Index. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns not significant

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us